G1 Therapeutics, Inc.

Good day and welcome to the G1 Therapeutics fourth quarter financial results conference call. At this time, all participants are in a listen-only mode. After the speaker presentation, there will be a question and answer session. To ask a question during the session, you will need to press star 1 1 on your telephone. You will then hear an automated message advising that your hand has been raised. To withdraw your question, please press star 1 1 again. Please be advised that today's conference is being recorded. It is now my pleasure to introduce Vice President of Communications, Will Roberts.

Thank you, Andrew. Good morning, everyone, and welcome to the G1 Conference call to discuss our fourth quarter and full year 2022 financial results and business update. The press release on these financial results was issued this morning and can be found in the news section of our corporate website, g1therapeutics.com. On this morning's call, the team will provide a business overview of the fourth quarter of 2022, including an update on our clinical programs and our commercial progress in that period with COSELLA, which is approved and commercially available to decrease the incidence of chemotherapy-induced myelosuppression in adult patients who had administered prior to a platinum atoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. A Q&A session will follow the prepared remarks. Before we begin, I'd like to remind you that today's webcast contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements represent management's judgment as of today and may involve risk and uncertainty that could cause actual results to differ materially from those expressed in or implied by these statements. For more information on such risk and uncertainties, please refer to our filings with the Securities and Exchange Commission, which are available from the SEC or on our corporate website. Any forward-looking statements represent our views as of today, March 1st, 2023. Joining me on the call today are Jack Bailey, our Chief Executive Officer, Raj Malek, our Chief Medical Officer, Andrew Perry, our Chief Commercial Officer, and Jen Moses, our Chief Financial Officer. And with that, I'll turn the call over to Jack.

Thanks, Will. Good morning, everyone, and thank you for joining us on the call today. We spoke with you just a couple of weeks ago on the PreserveOne results. Since that time, we continue to move forward with urgency on the rest of the business, focusing on three core goals. First, regarding sales and small cell lung cancer, we remain confident in the sales trajectory for Cosella in our first lung cancer indication. As you will hear from Andrew, our sales and marketing teams have executed well since the start of the fourth quarter of 2022, and bio volume growth returned after experiencing a flat third quarter. This has continued into the first quarter of 2023 with a record month of sales in January and our highest week ever of sales in February. Based on what we are seeing today, we expect our 2023 net co-seller sales to be in the range of $50 to $60 million, an increase of up to 92% over 2022. Second, as Raj will describe, we are focused on executing on our ongoing clinical trials to achieve near-term data readouts. In particular, our ADC and MOA phase twos and our phase three in triple negative breast cancer. Regarding the two phase twos, initial data were compelling. We observed clinically meaningful on-target effects of trilocyclic to reduce the rates of multiple adverse events when administered prior to the ADC thocituzumab, including myelosuppression and diarrhea. And the initial results from our mechanism of action trial in neoadjuvant TMBC showed favorable alterations in the tumor microenvironment from just a single dose of trilocyclic monotherapy. And third, we have moved quickly to make the necessary organizational changes to preserve capital, including reducing the workforce by nearly 30%, though the sales team remains intact. and also other prudent decisions to reduce spend and extend our cash runway through each of our clinical readouts, including the TMBC pivotal trial. Jen will provide more color on these topics. We will take these three goals in order. Andrew will first cover our recent commercial efforts since the start of the fourth quarter of 2022. Raj will then provide an update on our clinical program, including a brief overview of the results of PreserveOne and our efforts to understand those results. Finally, Jen will provide financial results for the quarter and, as mentioned, discuss the actions we have taken to extend our cash runway. Then I'll be back for some concluding comments. With that, I'll turn the call over to Andrew. Thank you, Jack.